Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis

Posted On: 2020-10-31 08:44:23 (Time Zone: Arizona, USA)


Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented positive, five-year Phase 3 data for ILUMYA® (tildrakizumab-asmn) from the combined reSURFACE 1 and reSURFACE 2 extension studies. Patients with moderate-to-severe plaque psoriasis who continued to receive ILUMYA through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety issues reported.1 These data were presented for the first time at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

"These results are important as we now have five-year data reinforcing our understanding that ILUMYA may provide patients with sustained skin clearance and a well understood safety profile that was comparable to placebo," said Richard Langley, M.D., FRCPC, professor of medicine and director of research, Department of Medicine, Dalhousie University. "ILUMYA is a valued option for patients in the treatment of moderate-to-severe plaque psoriasis, and these findings are reassuring for physicians and their patients living with this chronic disease."

In an analysis of the pooled reSURFACE 1 and reSURFACE 2 extension studies, patients received ILUMYA 100 mg or 200 mg through five years of continuous treatment. ILUMYA 100 mg is approved in the U.S., Japan and Australia, and 200 mg is additionally approved under the brand name ILUMETRI™ in Europe. In patients who were treated with ILUMYA 100 mg, clear or almost clear skin (PASI 90) was achieved by 65.9% of patients and 32.8% of patients achieved completely clear skin (PASI 100) at Week 244. The standard goal of treatment, a PASI 75 response, was achieved by 88.7% of patients at Week 244.1 The long-term analyses also showed absolute PASI <1/<3/<5 scores at Week 28 (50.8%, 85.1% and 96.4%, respectively) were sustained through Week 244 (47.7%, 78.8% and 88.7%, respectively).1 Absolute PASI scores can provide an indication of the extent of residual disease after treatment. Achievement of an absolute PASI score of <3 has been proposed as comparable to a PASI 90 response, which is equivalent to clear or almost clear skin.3

ILUMYA 100 mg was well-tolerated during the Phase 3 trials. The three adverse reactions that occurred more frequently than placebo and ≥1% in clinical trials were upper respiratory infections (14% vs. 12%), injection site reactions (3% vs. 2%) and diarrhea (2% vs. 1%). Furthermore, the analysis demonstrated similar exposure-adjusted incidence rates of malignancies throughout five years of study. A majority of malignancies were singular events with similar incidence rates as seen in the general US population.2

"These impressive results show that ILUMYA keeps working year-on-year, maintaining a high level of skin clearance and a durable safety profile regardless of baseline level of skin disease, age or background illnesses," said Abhay Gandhi, CEO, Sun Pharma, North America. "Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and we are pleased these data show that ILUMYA is a sustainable choice for patients over the long term."

ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses. See ongoing studies below for more information. Visit www.ILUMYA.com to learn more about the ILUMYA SUPPORT Lighting the Way® program that helps patients get started with treatment, understand cost and saving options, and connect with experts and others living with plaque psoriasis.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.465.75 as compared to the previous close of Rs. 456.75. The total number of shares traded during the day was 245758 in over 6145 trades.

The stock hit an intraday high of Rs. 468.85 and intraday low of 455.9. The net turnover during the day was Rs. 113622440.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Mr. Rajnikant D. Shroff, Chairman and Managing Director of UPL Ltd. conferred Padma Bhushan

Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg

Infosys Expands Relationship with Snowflake to Become Elite Service Partner

Quess Corp Limited approves investment in TaskMo, a digital gig worker platform

A. K. Capital Services Limited board declares interim dividend of Rs. 5 for FY21

SVP Global to raise ~ Rs 235 Cr via Equity Warrants, convertible at 37% premium to market price

Quess Corp Ltd Q3FY21 consolidated PAT at Rs. 41.75 crore

A K Capital Services Ltd Q3FY21 consolidated net profit zooms to Rs. 31.61 crore

Bhageria Industries Ltd Q3FY21 consolidated net profit rises to Rs. 22.48 crore

HUL announces key appointment to its Management Committee

Manorama Industries Limited recognized by Fair Trade and Fair for Life Certifications for its ESG Practices

Greenply Industries Ltd completes assessment conducted by Great Place to Work Institute

PVR Ltd opens QIP, fixes floor price as Rs. 1495.93 per share

CRISIL upgrades long-term rating of Endurance Technologies Limited

Aditya Birla Fashion and Retail Limited to acquire 51% in Sabyasachi Couture

Trio Mercantile & Trading Ltd Board recommends sub-division & bonus issue of equity shares

TATA Coffee Ltd Q3FY21 consolidated net profit climbs to Rs. 31.52 crore

United Spirits Ltd posts consolidated PAT of Rs. 287 crore in Q3 FY2020-21

Suraj Products Ltd Q3FY21 net profit zooms to Rs. 3.39 crore

Swastika Investmart Ltd reports Q3FY21 consolidated PAT of Rs. 2.42 crore

Cosmo Films Ltd board declares interim dividend of Rs. 25

Datamatics simplifies document processing with a new AI-enabled TruCap+ IDP solution

GMR Hyderabad International Airport Limited successfully prices $300 mn bond offering

ICICI Prudential Life Insurance Company Ltd reports Q3FY21 consolidated PAT of Rs. 304.30 crore

Lakshmi Machine Works Ltd Q3FY21 consolidated PAT surges to Rs. 33.26 crore

JK Paper Ltd reports Q3FY21 consolidated PAT of Rs. 65.94 crores

Titan Securities Ltd posts Rs. 2.67 crore consolidated PAT in Q3

Bannari Amman Sugars Ltd Q3FY21 net profit at Rs. 31.92 crores

Vakrangee Limited included in 2021 Bloomberg Gender-Equality Index

Government to divest MMTC Ltd's JV, Neelachal Ispat Nigam Ltd

Stylam Industries Ltd board to consider stock split on Feb 9, 2021

Cosmo Films Ltd posts Rs. 62.75 crores consolidated PAT in Q3 FY2020-21

Bella Casa Fashion & Retail Ltd board declares interim dividend of Rs. 0.60

Affle announces the global launch of Appnext OOBE platform powered by the acquisition of DiscoverTech

Hero MotoCorp partners with Grupo Salinas in Mexico

POWERGRID to sell units in POWERGRID Infrastructure Investment Trust

NALCO board approves buyback of equity shares at Rs. 57.50 per share

HOCL Q3FY21 consolidated PAT at Rs. 14.79 crore

Duncan Engineering Ltd Q3 net profit at Rs. 1.12 crore

Bella Casa Fashion & Retail Ltd reports Rs. 4 crore PAT in Q3

Titan Biotech Ltd posts Rs. 6.62 crore consolidated net profit in Q3FY21

Surya Roshni Ltd Q3FY21 consolidated PAT jumps to Rs. 55.62 crore

AXIS Bank Ltd reports Q3FY21 consolidated PAT of Rs. 1334.84 crores

Zodiac JRD MKJ Ltd Q3FY21 net profit at Rs. 0.13 crore

Mrs. Rajni Bector conferred with Padma Shri for her contribution to trade and industry

Nippon Life India Asset Management Ltd Q3FY21 consolidated PAT at Rs. 211.95 crore

Hindustan Unilever Ltd posts Q3FY21 consolidated PAT of Rs. 1937 crores

Bank of Baroda reports Q3FY21 earnings

Infosys Recognized as the Fastest Growing Top 10 IT Services Brand

Rama Phosphates Ltd updates on new projects to manufacture LABSA and Sulphuric Acid



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020